ARCHIVES

Five-Year Course of Tamoxifen Remains Standard Treatment In HR+ Breast Cancer

This article is from The Cancer Letter archive.

Vol. 25 No. 7 | July 26, 2002

Download PDF Visit The Full Archive

Related Articles

IOM, NCI Clash Over Proposed Change in Tabulating Minority Research

January 22, 1999

House Committee Allocates NCI $1.347 Billion, $189 Million Over President’s Request For 1987

August 1, 1986

No Constitutional Right To Experimental Drugs, Appeals Court Rules Against Abigail Alliance.

August 10, 2007

ACS-Roosevelt Awards Go to 19 New Fellows

July 30, 1976

“Dollars For Docs” Database Of Pharma Payments Posted By News Organization

October 22, 2010

Cancer Leadership Council letter calls for permanent leadership of NCI and FDA.

November 23, 2005